Martin Culjat

Martin Culjat

Company: Dthera Sciences

Job title: Senior Vice President, Scientific & Regulatory Affairs


Regulatory & Reimbursement Implications of FDA Breakthrough Device Designation 1:30 pm

• Overview of the FDA Breakthrough Devices program and eligibility criteria • Discussion on what Breakthrough Device designation might mean for digital therapeutics companies • Exploring emerging CMS reimbursement opportunities for Breakthrough devicesRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.